Higher PD-L1 expression is evident in cetuximab-resistant HNSCC cell lines, despite no corresponding rise in CD274 (which encodes PD-L1) mRNA levels, suggesting epigenetic modifications play a role in resistance [100]. Here, CD274 is linked to head and neck squamous cell carcinoma.